Full text is available at the source.
Abstract
Adults with Type 2 diabetes and diabetic foot ulcers treated with glucagon-like peptide-1 receptor agonists may have different lower extremity amputation risks compared to those on other glucose-lowering therapies.
- The study aims to evaluate the risk of lower extremity amputation in adults with Type 2 diabetes and diabetic foot ulcers.
- Comparison is made between glucagon-like peptide-1 receptor agonists and other glucose-lowering therapies.
- Peripheral arterial disease may influence the association between treatment type and amputation risk.
- The analysis is intended to replicate findings across different classes of comparator therapies.
Simplified